A pH-sensitive β-cyclodextrin-modified periodic mesoporous organosilica hybrid nanomaterial for co-delivery of Paclitaxel and curcumin in lung cancer

. However, the drug release profile results demonstrated that CUR was released much faster than PTX. The release of CUR in advance would allow effective chemosensitization of cancer cells, which in turn would increase the therapeutic efficacy of PTX. The results of the MTT study indicate that Paclitaxel and curcumin co-loaded β-CD-APTS-PMO had a better anticancer effect than free Paclitaxel or curcumin. These results indicate that β-CD-APTS-PMO is a promising nanocarrier candidate for the lung cancer combination therapy.